Yahoo · Oct 21, 2026
MHRA revokes approval for Valneva’s Ixchiq due to safety frailties
The market withdrawal caps a tumultuous few years for the chikungunya vaccine amid related adverse events.
VA
NASDAQ · VALN
Valneva SE
Healthcare · Biotechnology
$5.66
Down-$0.10 (-1.74%)
Updated Nov 15, 2026, 6:59 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 752.57M
- P/E ratio
- -9.07
- Dividend yield
- 0.00%
- 52-week range
- $4.75 – $12.18
- Volume
- 2.72K
- Avg. volume
- 41.67K
Price performance · VALN
VALN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 13, 2026
VALN closed at $5.66 after 20 trading sessions, up 2.72% for the selected period.
- Last close
- $5.66
- Period change
- +2.72%
- Period low
- $5.26
- Period high
- $5.92
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | $5.88 | $5.88 | $5.66 | $5.66 | 2.72K |
| Nov 12, 2026 | $5.91 | $5.91 | $5.7311 | $5.76 | 5.55K |
| Nov 11, 2026 | $5.84 | $5.955 | $5.51 | $5.92 | 50.01K |
| Nov 10, 2026 | $5.94 | $6.0399 | $5.79 | $5.87 | 24.43K |
| Nov 9, 2026 | $5.83 | $5.92 | $5.64 | $5.66 | 9.91K |
| Nov 6, 2026 | $5.50 | $5.64 | $5.4979 | $5.51 | 7.96K |
| Nov 5, 2026 | $5.70 | $5.78 | $5.6166 | $5.64 | 5.38K |
| Nov 4, 2026 | $5.69 | $5.77 | $5.63 | $5.63 | 6.67K |
| Nov 3, 2026 | $5.43 | $5.565 | $5.43 | $5.51 | 4.65K |
| Nov 2, 2026 | $5.347 | $5.37 | $5.3114 | $5.32 | 7.47K |
| Oct 30, 2026 | $5.61 | $5.61 | $5.40 | $5.45 | 7.93K |
| Oct 29, 2026 | $5.77 | $5.77 | $5.65 | $5.71 | 11.52K |
| Oct 28, 2026 | $5.60 | $5.74 | $5.57 | $5.74 | 3.85K |
| Oct 27, 2026 | $5.43 | $5.58 | $5.38 | $5.57 | 16.13K |
| Oct 26, 2026 | $5.37 | $5.475 | $5.32 | $5.41 | 21.3K |
| Oct 23, 2026 | $5.2573 | $5.295 | $5.25 | $5.26 | 6.41K |
| Oct 22, 2026 | $5.49 | $5.61 | $5.31 | $5.36 | 22.62K |
| Oct 21, 2026 | $5.75 | $5.75 | $5.5301 | $5.56 | 137.26K |
| Oct 20, 2026 | $5.54 | $5.84 | $5.54 | $5.69 | 13.1K |
| Oct 19, 2026 | $5.53 | $5.53 | $5.40 | $5.51 | 9.14K |
Latest VALN news
The latest Smart Investors Daily articles mentioning VALN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VALN research
Overview
Company profile and research snapshot.
Company profile
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $14.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Aug 14, 2026 | STIFEL EUROPE | Buy | — |
| Aug 6, 2026 | PORTZAMPARC BNP PARIBAS | Buy | — |
| Jul 13, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Jul 12, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 14, 2026
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Lyon (France), October 14, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in meetings with institutional investors at upcoming investor conferences in the United States and Europe. In addition to meeting with investors, Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the regulatory outlook for the Compa
Benzinga · Oct 14, 2026
Full Transcript: Valneva Q2 2026 Earnings Call
Valneva (NASDAQ:VALN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
Yahoo · Oct 5, 2026
Declaration of shares and voting rights - Status as of September 30, 2026
VALNEVA Declaration of shares and voting rights Status as of September 30, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: October 5, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Descr
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
